Revolution Medicines, Inc. (RVMD)财务
NASDAQ · Healthcare · Biotechnology · 员工883人 · CEO Mark A. Goldsmith
- 股价
- $191.31 +0.55%
- 市值
- $410亿
- 企业价值
- $408亿
- 最近财报
- Q2 '26 2026-08-05提交
- 下次财报
- 2026-11-04 EPS预期 -$2.35
营收(TTM)$0– 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)–– 对比去年同期营业利润 -$16.3亿
净利润(TTM)-$17.7亿-117.8% 对比去年同期税后,含营业外收益
自由现金流(TTM)-$12.3亿-75.9% 对比去年同期资本支出 $910万
稀释EPS(TTM)-$8.86-96.5% 对比去年同期最近4个季度之和
净现金$33亿+64.4% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $410亿 EV $408亿
- 营收
- $0 过去12个月
- 营收增速
- – FY2026年一致预期
- 净利润率
- – 净利润 / 营收,TTM
- P/E
- -21.6× 预期 -20.2×(FY2026)
- P/S
- 0.0× 股价 / 营收,TTM
- EV / EBITDA
- -24.1× TTM
- 自由现金流
- -$12.3亿 过去12个月
- 净利润
- -$17.7亿 过去12个月
- 营收预期
- $2.08亿 FY2026年一致预期
- 盈利
- 2026-11-04 营收预期 $2560万
- 股息
- – 无股息
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-08-05):营收无,EPS 低于预期50.0%营收–,预期$177万(–);EPS -$3.06,预期-$2.04(-50.0%)。
- 稀释股数一年内增加12.1%Q2 '26稀释股数2.11亿,一年前为1.88亿。
- 净现金 $33亿现金 + 短期投资 $39.4亿,含租赁债务 $6.42亿;一年前净现金 $20亿。
上一季度:Q2 '26
截至2026-06-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q2 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $0 | $0 | – |
| 营业利润 | -$5.05亿 | -$2.65亿 | -90.8% |
| 净利润 | -$6.44亿 | -$2.48亿 | -160.1% |
| 稀释EPS | -$3.06 | -$1.31 | -133.6% |
| 经营现金流 | -$3.87亿 | -$2.22亿 | -74.7% |
| 资本支出 | $229万 | $745万 | -69.3% |
| 自由现金流 | -$3.9亿 | -$2.29亿 | -70.0% |
| R&D | $3.95亿 | $2.24亿 | +76.2% |
| 股权激励费用 | $0 | $2880万 | -100.0% |
实际 vs 一致预期
2026-08-05| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| EPS(一致预期口径) | -$3.06 | -$2.04 | -50.0% |
来自2026-08-05发布的Q2 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q1 '23 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Collaboration Revenue Member | $701万 | – | 100.0% | $3480万 | – |
利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- -$12.2亿
- 资本支出
- -$910万
- 股票回购
- $0
- 股息
- $0
- 收购
- $0
- 债务净发行
- $9.76亿
- 股权激励费用
- $1.52亿
- 自由现金流
- -$12.3亿
- 股东回报 / FCF
- 0.0%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | -21.6× | – | – |
| EV / EBITDA | -24.1× | – | – |
| EV / 营收 | 0.0× | 113.4× 5年中的3年 | 51.5× – 227.7× |
| 股价 / FCF | -33.3× | – | – |
| 股价 / 净资产 | 15.5× | 4.0× | 1.8× – 9.3× |
| FCF收益率 | -3.0% | -9.1% | -12.2% – -6.0% |
| 投入资本回报率 | -40.8% | -34.4% | -56.8% – -25.1% |
| 净资产收益率 | -96.4% | -37.4% | -69.3% – -23.9% |
分析师
一致目标价 $253.47 (+32.5%)
区间 $179.00 – $320.00 · 评级 Buy
强烈买入1
买入22
持有2
卖出0
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $2.08亿 | – | -$9.49 | -59.5% | -20.2× | 19 |
| FY2027 | $12.3亿 | +492.6% | -$5.79 | +39.0% | -33.0× | 19 |
| FY2028 | $26.1亿 | +111.9% | -$2.41 | +58.5% | -79.5× | 18 |
| FY2029 | $50亿 | +91.5% | $5.82 | +342.0% | 32.9× | 9 |
| FY2030 | $81.6亿 | +63.2% | $15.21 | +161.2% | 12.6× | 8 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Revolution Medicines, Inc.在近期10-Q / 10-K文件中标记的全部205项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $8840万 | $5680万 | +55.8% | $6460万 | $5440万 | +18.7% |
| Accretion (Amortization) of Discounts and Premiums, Investments | $433万 | $774万 | -44.0% | $2780万 | $4460万 | -37.5% |
| Accrued Employee Benefits, Current | $6470万 | $2170万 | +197.7% | $5820万 | $3080万 | +89.1% |
| Accrued Liabilities, Current | $500万2026-03-31 | – | – | $500万 | – | – |
| Accrued Professional Fees, Current | $894万 | $291万 | +206.9% | $614万 | $162万 | +278.1% |
| Accrued Royalties | $5.49亿 | $2.45亿 | +123.8% | $2.68亿 | $0 | – |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $3280万 | $2500万 | +31.2% | $2850万 | $2180万 | +30.7% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$595万 | $130万 | -557.0% | $324万 | $132万 | +145.0% |
| Additional Paid in Capital, Common Stock | $65.8亿 | $40.6亿 | +61.9% | $45亿 | $40亿 | +12.4% |
| Adjustments to Additional Paid in Capital, Warrant Issued | – | – | – | $9540万2024-12-31 | – | – |
| Amortization of Debt Issuance Costs | $41.9万 | – | – | $54.1万 | – | – |
| Amortization of Intangible Assets | $0 | $30万 | -100.0% | $87万 | $107万 | -18.6% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 116万 | 70.4万 | +65.0% | 2450万 | 1940万 | +26.2% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $6700万 | $2880万 | +132.4% | $1.18亿 | $7920万 | +49.5% |
| Asset Impairment Charges | $02025-09-30 | $0 | – | – | – | – |
| Assets | $43.2亿 | $24.3亿 | +77.9% | $23.5亿 | $25.6亿 | -8.0% |
| Assets, Current | $40.3亿 | $21.8亿 | +85.1% | $20.8亿 | $23.3亿 | -10.9% |
| Business Combination, Consideration Transferred | – | – | – | $11亿 | $11亿 | 0.0% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents | $8.61亿2025-12-31 | $8.61亿 | 0.0% | $8.61亿 | $8.61亿 | 0.0% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability | $49万2025-12-31 | $49万 | 0.0% | $49万 | $49万 | 0.0% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities | $3.14亿2025-12-31 | $3.14亿 | 0.0% | $3.14亿 | $3.14亿 | 0.0% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets | $1210万2025-12-31 | $1210万 | 0.0% | $1210万 | $1210万 | 0.0% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable | $689万2025-12-31 | $689万 | 0.0% | $689万 | $689万 | 0.0% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | $11.5亿2025-12-31 | $11.5亿 | 0.0% | $11.5亿 | $11.5亿 | 0.0% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | $291万2025-12-31 | $291万 | 0.0% | $291万 | $291万 | 0.0% |
| Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net | $5590万2025-12-31 | $5590万 | 0.0% | $5590万 | $5590万 | 0.0% |
| Capital Expenditures Incurred but Not yet Paid | $300万 | $12.2万 | +2,354.9% | $188万 | $158万 | +19.0% |
| Cash and Cash Equivalents, at Carrying Value | $8.15亿 | $4.02亿 | +102.6% | $3.84亿 | $5.43亿 | -29.3% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $8.2亿 | $4.06亿 | +101.9% | $3.89亿 | $5.47亿 | -28.9% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | $8.2亿 | $4.06亿 | +101.9% | $3.89亿 | $5.47亿 | -28.9% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $3.74亿 | $6910万 | +441.9% | -$1.58亿 | -$1.52亿 | -3.8% |
| Common Stock, Capital Shares Reserved for Future Issuance | 3770万 | 3290万 | +14.6% | 2860万 | 3170万 | -9.7% |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | 0.0% | $0.00 | $0.00 | 0.0% |
| Common Stock, Shares Authorized | 3亿 | 3亿 | 0.0% | 3亿 | 3亿 | 0.0% |
| Common Stock, Shares, Issued | 2.14亿 | 1.87亿 | +14.6% | 1.97亿 | 1.86亿 | +6.0% |
| Common Stock, Shares, Outstanding | 2.14亿 | 1.87亿 | +14.6% | 1.97亿 | 1.86亿 | +6.0% |
| Common Stock, Value, Issued | $2.1万 | $1.8万 | +16.7% | $1.9万 | $1.8万 | +5.6% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$6.5亿 | -$2.48亿 | -161.8% | -$11.3亿 | -$5.99亿 | -88.4% |
| Convertible Notes Payable, Noncurrent | $4.87亿 | – | – | – | – | – |
| Current Federal Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Current Foreign Tax Expense (Benefit) | – | – | – | $0 | -$4.2万 | +100.0% |
| Current Income Tax Expense (Benefit) | – | – | – | $0 | -$1.5万 | +100.0% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $0 | $2.7万 | -100.0% |
| Debt Securities, Available-for-sale | $38.8亿 | $21.4亿 | +81.8% | $20.2亿 | $22.9亿 | -11.5% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $15.1万 | $159万 | -90.5% | $328万 | $187万 | +75.8% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $600万 | $29.2万 | +1,954.8% | $4.4万 | $54.5万 | -91.9% |
| Debt Securities, Available-for-sale, Amortized Cost | $38.9亿 | $21.4亿 | +82.1% | $20.2亿 | $22.9亿 | -11.6% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $0 | -$1.7万 | +100.0% |
| Deferred Income Tax Expense (Benefit) | – | – | – | $0 | -$73.8万 | +100.0% |
| Deferred Income Tax Liabilities, Net | $235万 | $235万 | 0.0% | $235万 | $235万 | 0.0% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $0 | -$72.1万 | +100.0% |
| Deferred Tax Assets, Gross | $9.82亿2025-12-31 | $6.09亿 | +61.3% | $9.82亿 | $6.09亿 | +61.3% |
| Deferred Tax Assets, Net of Valuation Allowance | $5390万2025-12-31 | $4510万 | +19.5% | $5390万 | $4510万 | +19.5% |
| Deferred Tax Assets, Operating Loss Carryforwards | $4.36亿2025-12-31 | $2.27亿 | +92.3% | $4.36亿 | $2.27亿 | +92.3% |
| Deferred Tax Assets, Other | $110万2025-12-31 | $114万 | -3.7% | $110万 | $114万 | -3.7% |
| Deferred Tax Assets, Tax Credit Carryforwards, Research | $1.32亿2025-12-31 | $6600万 | +100.2% | $1.32亿 | $6600万 | +100.2% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $3350万2025-12-31 | $2020万 | +65.5% | $3350万 | $2020万 | +65.5% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals | $2030万2025-12-31 | $995万 | +103.9% | $2030万 | $995万 | +103.9% |
| Deferred Tax Assets, Valuation Allowance | $9.29亿2025-12-31 | $5.64亿 | +64.7% | $9.29亿 | $5.64亿 | +64.7% |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标、预期:Financial Modeling Prep。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
数据截至 2026-11-02